• Markets
  • icon
  • Companies
CYC · ASX

Cyclopharm Limited (ASX:CYC)

AU$1.65

 0.09 (5.769%)
ASX:Live
22/05/2024 04:10:12 PM
Near Support Near 52 Week Low Hammer Bearish HALO Ords HALO Consensus Value +4
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

CYC Overview

CYC Health Scores

Short Term

Mean Revision

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Neutral

Balance Sheet

Very Strong

About CYC

Telephone

Address

Description

Cyclopharm Ltd. is a radiopharmaceutical company, which engages in diagnostic imaging in lung health. It manufactures and sells medical devices and pharmaceutical products. It operates through Technegas and Molecular Imaging segments. The Technegas segment supplies diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. The Molecular Imaging segment produces radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders and cardiac disease. The company was founded in 1984 and is headquartered in Kingsgrove, Australia.

CYC Price Chart

Key Stats

Market Cap

AU$146.94M

PE

0.00

EV/EBITDA

0.0

Dividends Overview

DIV Yield

.6%

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 1.54 - 3.15

Trade Value (12mth)

AU$17,504.00

1 week

-5.45%

1 month

-12.36%

YTD

-18.32%

1 year

-25.36%

All time high

3.450000047683716

Key Fundamentals

EPS 3 yr Growth

-35.700%

EBITDA Margin

-33.20%

Operating Cashflow

-$7m

Free Cash Flow Return

-18.60%

ROIC

-12.20%

Interest Coverage

-40.50

Quick Ratio

2.30

Other Data

Shares on Issue (Fully Dilluted)

N/A

HALO Sector

Next Company Report Date

19-Feb-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

CYC Announcements

Latest Announcements

Date Announcements

16 May 24

Appendix 3C Final buy-back notification

×

Appendix 3C Final buy-back notification

06 May 24

Cyclopharm Business Update

×

Cyclopharm Business Update

26 April 24

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

26 April 24

Becoming a substantial holder

×

Becoming a substantial holder

24 April 24

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

08 April 24

Application for quotation of securities - CYC

×

Application for quotation of securities - CYC

26 March 24

Annual Report to shareholders

×

Annual Report to shareholders

26 March 24

Appendix 4G

×

Appendix 4G

25 March 24

Date of Annual General Meeting

×

Date of Annual General Meeting

25 March 24

Voluntary Escrow Shares to be Released

×

Voluntary Escrow Shares to be Released

19 March 24

First USA Patients Imaged with Technegas

×

First USA Patients Imaged with Technegas

01 March 24

S&P DJI Announces March 2024 Quarterly Rebalance

×

S&P DJI Announces March 2024 Quarterly Rebalance

28 February 24

Preliminary Final Report

×

Preliminary Final Report

28 February 24

CYC Results Summary

×

CYC Results Summary

19 February 24

CYC Board Changes

×

CYC Board Changes

19 February 24

Initial Director's Interest Notice

×

Initial Director's Interest Notice

12 February 24

Cyclopharm Appoints Jason Smith as CFO

×

Cyclopharm Appoints Jason Smith as CFO

06 February 24

Cyclopharm to Present at Euroz Hartleys Healthcare Forum

×

Cyclopharm to Present at Euroz Hartleys Healthcare Forum

05 February 24

Cyclopharm Trading and USA Launch Update

×

Cyclopharm Trading and USA Launch Update

29 January 24

CYC and Yale Translational Research Partner on Technegas

×

CYC and Yale Translational Research Partner on Technegas

05 December 23

Cyclopharm Signs First USA Contract for Technegas

×

Cyclopharm Signs First USA Contract for Technegas

01 December 23

Application for quotation of securities - CYC

×

Application for quotation of securities - CYC

01 December 23

Change of Director's Interest Notice

×

Change of Director's Interest Notice

15 November 23

Technegas USA Commercialisation Update

×

Technegas USA Commercialisation Update

02 November 23

Change of Director's Interest Notice

×

Change of Director's Interest Notice

CYC Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.06 -0.07 -0.05 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.06 -0.07 -0.05 Lock Lock Lock
     Growth % Lock Lock Lock Lock 28.6 -27.4 29.3 Lock Lock Lock
     PE X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.03 -0.06 -0.06 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.04 -0.10 -0.09 Lock Lock Lock
     Growth % Lock Lock Lock Lock 33.6 -63.7 -15.3 Lock Lock Lock
     Yield % Lock Lock Lock Lock -2.3 -8.2 -4.6 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.01 0.01 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 0.0 0.0 -100.0 Lock Lock Lock
     Yield % Lock Lock Lock Lock 0.6 0.8 0.6 Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.46 0.39 0.34 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.40 0.33 0.28 Lock Lock Lock
     Growth % Lock Lock Lock Lock 173.7 -17.1 -15.7 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 90 92 93 Lock Lock Lock
Basic m Lock Lock Lock Lock 90 92 93 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 18 23 26 Lock Lock Lock
     Growth % Lock Lock Lock Lock 20.6 31.1 13.4 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 10 13 13 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 3 6 4 Lock Lock Lock
     Growth % Lock Lock Lock Lock 54.0 85.5 -37.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock 18.1 25.6 14.0 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 82 74 86 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -6 -6 -9 Lock Lock Lock
     Growth % Lock Lock Lock Lock 20.9 -11.9 -37.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -32.1 -27.3 -33.2 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -6 -7 -10 Lock Lock Lock
     Growth % Lock Lock Lock Lock 20.4 -13.1 -33.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -36.3 -31.4 -36.8 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -7 -8 -4 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -2 -1 1 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -5 -7 -5 Lock Lock Lock
     Growth % Lock Lock Lock Lock 16.6 -31.2 28.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -28.5 -28.5 -17.8 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -2 -7 -7 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 1 2 1 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -1 -2 -1 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 30 -1 -1 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -2 -8 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock 72.9 -221.1 6.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -0.1 -0.3 -0.3 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 29 20 12 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 56 50 46 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 4 4 4 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -25 -16 -7 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 13 13 14 Lock Lock Lock
Equity $m Lock Lock Lock Lock 43 37 32 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 47 41 36 Lock Lock Lock
     Growth % Lock Lock Lock Lock 118.7 -14.2 -10.8 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -9.0 -13.3 -10.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -11.7 -18.1 -14.6 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -18.5 -16.5 -25.0 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -14.6 -15.0 -12.2 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -4.7 -15.1 -18.6 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -63.5 -23.9 -40.5 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 4.4 2.5 0.9 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -57.4 -43.7 -23.2 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 5.8 4.6 3.5 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 5.1 3.6 2.3 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 67.6 55.0 38.8 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -22.0 -84.0 -82.7 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 2.1 2.9 3.4 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 2.8 2.5 2.5 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.5 0.8 1.2 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 12.3 18.9 11.9 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.3 0.5 0.6 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.3 0.5 0.6 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -37.5 -33.0 -15.9 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -11.9 -15.5 -9.1 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -9.0 -13.3 -10.2 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.3 1.4 1.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -11.7 -18.1 -14.6 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 117.8 113.9 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -13.8 -20.6 -14.6 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 129.0 145.8 148.4 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 177.0 124.3 108.1 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 306.0 270.1 256.6 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 65.4 59.8 56.3 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 240.6 210.3 200.3 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

.6%

Franking Level

N/A

DPSg

-100.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Expected Dividend Cashflow

Dividend Clarity,
Enhanced
Strategy

Upload your portfolio and gain access to 3-year dividend forecasts for each holding with HALO Global. Empower your decision-making and maximize returns with our advanced analytical tool. Try it today.

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

CYC Shortsell

Frequently Asked Questions

The current share price of Cyclopharm Limited (CYC:ASX) is AU$1.65.
The 52-week high share price for Cyclopharm Limited (CYC:ASX) is AU$3.15.
The 52-week low share price for Cyclopharm Limited (CYC:ASX)? is AU$1.54.
The current TTM dividend payout for Cyclopharm Limited (CYC:ASX) is 0.60.
The last dividend payment of Cyclopharm Limited (CYC:ASX) is AU$0.01.
Cyclopharm Limited (CYC:ASX) has a franking level of 0.0%.
Cyclopharm Limited (CYC:ASX) is classified in the Healthcare.
The current P/E ratio for Cyclopharm Limited (CYC:ASX) is 0.00.